通过高亲和力重组抗体鉴定胶质母细胞瘤相关的腱生蛋白-C异构体
Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody.
作者信息
Carnemolla B, Castellani P, Ponassi M, Borsi L, Urbini S, Nicolo G, Dorcaratto A, Viale G, Winter G, Neri D, Zardi L
机构信息
Laboratory of Cell Biology and Laboratory of Anatomic Pathology, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy.
出版信息
Am J Pathol. 1999 May;154(5):1345-52. doi: 10.1016/S0002-9440(10)65388-6.
Abstract
Tenascin-C exists in several polymorphic isoforms due to alternative splicing of nine fibronectin-like type III repeats. Large Tenascin-C isoforms are present in almost all normal adult tissues but are upregulated in fetal, regenerating, and neoplastic tissues. Here, we report a human antibody fragment, TN11, derived from a phage library with high affinity for the spliced repeat C and demonstrate that this repeat is undetectable in normal adult tissues, barely detectable or undetectable in breast, lung and gastric carcinomas, meningioma, and low grade astrocytoma, but extremely abundant in high grade astrocytoma (grade III and glioblastoma), especially around vascular structures and proliferating cells. The antibody appears to have potential for development of a therapeutic agent for patients with high grade astrocytoma.
摘要
由于九个纤连蛋白样III型重复序列的可变剪接，腱生蛋白-C以几种多态性异构体形式存在。大的腱生蛋白-C异构体几乎存在于所有正常成人组织中，但在胎儿、再生和肿瘤组织中上调。在此，我们报道了一种源自噬菌体文库的人抗体片段TN11，它对剪接重复序列C具有高亲和力，并证明该重复序列在正常成人组织中无法检测到，在乳腺癌、肺癌和胃癌、脑膜瘤及低级别星形细胞瘤中几乎检测不到或无法检测到，但在高级别星形细胞瘤（III级和胶质母细胞瘤）中极其丰富，尤其是在血管结构和增殖细胞周围。该抗体似乎有开发用于高级别星形细胞瘤患者治疗药物的潜力。
相似文献
1
Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody.通过高亲和力重组抗体鉴定胶质母细胞瘤相关的腱生蛋白-C异构体
Am J Pathol. 1999 May;154(5):1345-52. doi: 10.1016/S0002-9440(10)65388-6.
2
Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C.针对腱生蛋白-C 大异构体的新型抗体的肿瘤靶向特性
Clin Cancer Res. 2006 May 15;12(10):3200-8. doi: 10.1158/1078-0432.CCR-05-2804.
3
Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma.腱生蛋白-C在各种人脑肿瘤中的表达及其与星形细胞瘤患者生存的相关性。
Cancer. 2003 Dec 1;98(11):2430-9. doi: 10.1002/cncr.11796.
4
Specific processing of tenascin-C by the metalloprotease meprinbeta neutralizes its inhibition of cell spreading.基质金属蛋白酶 meprinβ对 tenascin-C 的特异性加工可中和其对细胞铺展的抑制作用。
Matrix Biol. 2010 Jan;29(1):31-42. doi: 10.1016/j.matbio.2009.08.007. Epub 2009 Sep 12.
5
Changes in tenascin-C isoform expression in invasive and preinvasive breast disease.浸润性和癌前乳腺疾病中肌腱蛋白-C异构体表达的变化
Cancer Res. 2002 Jun 1;62(11):3289-97.
6
Glial tumor cell adhesion is mediated by binding of the FNIII domain of receptor protein tyrosine phosphatase beta (RPTPbeta) to tenascin C.胶质肿瘤细胞黏附是由受体蛋白酪氨酸磷酸酶β（RPTPβ）的纤连蛋白III结构域与腱生蛋白C结合介导的。
Oncogene. 2001 Feb 1;20(5):609-18. doi: 10.1038/sj.onc.1204119.
7
Tenascin mRNA isoforms in the developing mouse brain.发育中小鼠大脑中的腱生蛋白mRNA亚型。
J Neurosci Res. 1994 Feb 15;37(3):336-47. doi: 10.1002/jnr.490370306.
8
Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo.抗腱生蛋白-C结构域C的人单克隆抗体在体内可选择性靶向实体瘤。
Protein Eng Des Sel. 2006 Oct;19(10):471-8. doi: 10.1093/protein/gzl033. Epub 2006 Aug 22.
9
The expression of tenascin-C with the AD1 variable repeat in embryonic tissues, cell lines and tumors in various vertebrate species.在各种脊椎动物物种的胚胎组织、细胞系和肿瘤中，含AD1可变重复序列的肌腱蛋白-C的表达情况。
Differentiation. 1997 Nov;62(2):71-82. doi: 10.1046/j.1432-0436.1997.6220071.x.
10
Differential distribution of tenascin in the normal, hyperplastic, and neoplastic breast.腱生蛋白在正常、增生及肿瘤性乳腺组织中的差异分布。
Lab Invest. 1990 Dec;63(6):798-806.
引用本文的文献
1
The Microenvironment in DCIS and Its Role in Disease Progression.导管原位癌中的微环境及其在疾病进展中的作用。
Adv Exp Med Biol. 2025;1464:211-235. doi: 10.1007/978-3-031-70875-6_12.
2
Protease-activated CendR peptides targeting tenascin-C: mitigating off-target tissue accumulation.靶向 tenascin-C 的蛋白酶激活 CendR 肽：减轻非靶组织蓄积。
Drug Deliv Transl Res. 2024 Oct;14(10):2945-2961. doi: 10.1007/s13346-024-01670-2. Epub 2024 Jul 16.
3
In Vitro Study of Tumor-Homing Peptide-Modified Magnetic Nanoparticles for Magnetic Hyperthermia.肿瘤归巢肽修饰磁性纳米粒子用于磁热疗的体外研究。
Molecules. 2024 Jun 3;29(11):2632. doi: 10.3390/molecules29112632.
4
Biology of Tenascin C and its Role in Physiology and Pathology.Tenascin C 的生物学特性及其在生理学和病理学中的作用。
Curr Med Chem. 2024;31(19):2706-2731. doi: 10.2174/0929867330666230404124229.
5
PL1 Peptide Engages Acidic Surfaces on Tumor-Associated Fibronectin and Tenascin Isoforms to Trigger Cellular Uptake.PL1肽与肿瘤相关纤连蛋白和腱生蛋白异构体上的酸性表面结合，以触发细胞摄取。
Pharmaceutics. 2021 Nov 24;13(12):1998. doi: 10.3390/pharmaceutics13121998.
6
Novel Human Tenascin-C Function-Blocking Camel Single Domain Nanobodies.新型人 tenascin-C 功能阻断骆驼单域纳米抗体。
Front Immunol. 2021 Mar 15;12:635166. doi: 10.3389/fimmu.2021.635166. eCollection 2021.
7
Homing Peptides for Cancer Therapy.用于癌症治疗的归巢肽。
Adv Exp Med Biol. 2021;1295:29-48. doi: 10.1007/978-3-030-58174-9_2.
8
Alternative splicing in endothelial cells: novel therapeutic opportunities in cancer angiogenesis.内皮细胞中的可变剪接：癌症血管生成中的新治疗机会。
J Exp Clin Cancer Res. 2020 Dec 7;39(1):275. doi: 10.1186/s13046-020-01753-1.
9
Pleiotropic Role of Tenascin-C in Central Nervous System Diseases: From Basic to Clinical Applications.腱生蛋白-C在中枢神经系统疾病中的多效性作用：从基础研究到临床应用
Front Neurol. 2020 Nov 13;11:576230. doi: 10.3389/fneur.2020.576230. eCollection 2020.
10
Down-regulation of tenascin-C inhibits breast cancer cells development by cell growth, migration, and adhesion impairment.下调 tenascin-C 通过抑制细胞生长、迁移和黏附来抑制乳腺癌细胞的发展。
PLoS One. 2020 Aug 20;15(8):e0237889. doi: 10.1371/journal.pone.0237889. eCollection 2020.
本文引用的文献
1
Expression of the rat homologue of the Drosophila fat tumour suppressor gene.果蝇脂肪肿瘤抑制基因大鼠同源物的表达
Mech Dev. 1999 Feb;80(2):207-12. doi: 10.1016/s0925-4773(98)00217-2.
2
Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library.从一个大型未免疫噬菌体展示文库中分离出具有亚纳摩尔亲和力的人源抗体。
Nat Biotechnol. 1996 Mar;14(3):309-14. doi: 10.1038/nbt0396-309.
3
Local application of radiolabeled monoclonal antibodies in the treatment of high grade malignant gliomas: a six-year clinical experience.
Cancer. 1997 Dec 15;80(12 Suppl):2733-42. doi: 10.1002/(sici)1097-0142(19971215)80:12+<2733::aid-cncr53>3.3.co;2-8.
4
Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform.
Nat Biotechnol. 1997 Nov;15(12):1271-5. doi: 10.1038/nbt1197-1271.
5
Human tenascin-C: identification of a novel type III repeat in oral cancer and of novel splice variants in normal, malignant and reactive oral mucosae.
Int J Cancer. 1997 Jul 17;72(2):236-40. doi: 10.1002/(sici)1097-0215(19970717)72:2<236::aid-ijc6>3.0.co;2-s.
6
Biodistribution of 111In-labelled SCN-bz-DTPA-BC-2 MAb following loco-regional injection into glioblastomas.
Int J Cancer. 1997 May 29;71(5):810-6. doi: 10.1002/(sici)1097-0215(19970529)71:5<810::aid-ijc19>3.0.co;2-b.
7
Phage antibodies with pan-species recognition of the oncofoetal angiogenesis marker fibronectin ED-B domain.对癌胚血管生成标志物纤连蛋白ED-B结构域具有全物种识别能力的噬菌体抗体。
Int J Cancer. 1996 Nov 4;68(3):397-405. doi: 10.1002/(SICI)1097-0215(19961104)68:3<397::AID-IJC20>3.0.CO;2-4.
8
Extracellular pH controls pre-mRNA alternative splicing of tenascin-C in normal, but not in malignantly transformed, cells.
Int J Cancer. 1996 May 29;66(5):632-5. doi: 10.1002/(SICI)1097-0215(19960529)66:5<632::AID-IJC9>3.0.CO;2-U.
9
10
Intralesional radioimmunotherapy of malignant gliomas. An effective treatment in recurrent tumors.恶性胶质瘤的瘤内放射免疫疗法。复发性肿瘤的有效治疗方法。
Cancer. 1994 Feb 1;73(3 Suppl):1076-82. doi: 10.1002/1097-0142(19940201)73:3+<1076::aid-cncr2820731347>3.0.co;2-z.
Zotero 插件